Anavex Reports Findings from Phase IIb/III Trial for Once Daily Oral Dementia Treatment
Anavex Life Sciences has announced results from its ANAVEX2-73-AD-004 Phase IIb/III trial, highlighting the efficacy and safety of blarcamesine (ANAVEX 2-73), a small-molecule treatment…